

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 8-K

INTEGRATED BIOPHARMA INC  
Form 8-K  
June 28, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2004

Integrated BioPharma, Inc.  
-----

(Exact name of registrant as specified in its charter)

Delaware -----	000-28876 -----	22-2407475 -----
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

225 Long Avenue Hillside, New Jersey -----	07205 -----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (973) 926-0816

Not Applicable  
(Former name or former address, if changed since last report)

Item 5. Other Events and Regulation FD Disclosure.

On June 25, 2004, Integrated BioPharma, Inc., a Delaware corporation (the "Company"), issued a press release announcing its discovery that its common stock had been listed without its knowledge, consent or authority on a German stock exchange. The press release is attached as an exhibit to this Report.

Item 7. Financial Statements and Exhibits

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 8-K

(c) Exhibits.

Exhibit No. Description

99.1 Press Release issued by Integrated BioPharma, Inc. on June 25, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 28, 2004

INTEGRATED BIOPHARMA, INC.

By: /s/ Eric Friedman  
Eric Friedman  
Vice President and Chief Financial Officer

Exhibit Index

Exhibit No. Description

99.1 Press Release issued by Integrated BioPharma, Inc. on June 25, 2004